LUNGevity’s board of directors brings to the Foundation decades of experience in corporate management. Our members bring expertise in law, finance, marketing and communications, organizational best practices, and strategic planning to their governance of the organization. In addition, because each has been personally touched by lung cancer, the directors know the urgency associated with lung cancer research. They lend their proficiency, knowledge, and hearts to our endeavor to transform lung cancer.

Lynne Doughtie

Lynne Doughtie

Chair

Lynne Doughtie is former U.S. Chairman and Chief Executive Officer of KPMG — one of the world’s leading professional services firms. She also was a member of KPMG’s Global Board and Executive Committee.


Nichelle Stigger

Nichelle Stigger

Secretary

Nichelle Stigger is a lung cancer survivor-advocate whose cancer journey began in 2016 when she was diagnosed with a rare form of lung cancer, mucinous adenocarcinoma, found in only 1% of cancer patients.


Alexander F. Stern

Alexander F. Stern

Treasurer

Alex leads IBM’s strategy and mergers & acquisitions organizations, and also leads the company’s investor relations organization.


Andrea Ferris

Andrea E. Ferris

Member

Andrea is President and CEO of LUNGevity and a member of the Board of Directors. In her role as President and CEO of LUNGevity, Andrea is responsible for setting and executing the strategic direction of the organization and its science programs.


William “BJ” Jones

William “BJ” Jones

Member

William “BJ” Jones is the Chief Commercial Officer (CCO) at NewAmsterdam Pharma. As NewAmsterdam’s first-ever CCO, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement, and commercial operations.


Jennifer Kashatus

Jennifer Kashatus

Member

Jennifer Kashatus is a partner in the Washington, DC, office of DLA Piper LLP. Jennifer routinely advises companies in all industry sectors on privacy and cybersecurity issues.


Michael Kolodziej, MD

Michael Kolodziej, MD

Member

Michael Kolodziej, MD, serves as Senior Adviser for ADVI Health. He joined ADVI in October 2017. He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.


Michael Marquis

Michael Marquis

Member

Michael is a global business executive and consumer goods strategist with 25+ years of experience building high-performance teams and billion-dollar multinational brands in the worldwide retail marketplace.


Andre Owens

Andre Owens

Member

Andre is a partner at WilmerHale, a legal practice that focuses on securities trading and markets activities. He counsels broker-dealers, securities exchanges, investment advisers, and other clients on a variety of regulatory issues. Andre also provides advice with respect to acquisitions of securities broker-dealers and investment advisers.


Michael Parisi

Michael Parisi

Member

Michael has over 25 years of diverse healthcare industry experience with an intense focus on biotechnology and oncology. Currently, he is Global Practice Lead, Medical Strategy and Communications, at Lumanity, a diversified healthcare communications and market development agency.


Charles M. Rudin, MD, PhD

Charles Rudin, MD, PhD

Member

“Every week I see patients with this disease. Every week patients suffer relapses. I have watched too many lung cancer patients die. I am trying to change the outcome for patients with this disease.” — Charles M. Rudin, MD, PhD, Chair of the Scientific Advisory Board


Andrew Stern

Andrew Stern

Member

Andrew Stern has spent his entire career focused on early stage company development, financing and operations.


Paul G. Stern

Paul G. Stern

Member

Paul founded Protect Your Lungs after his wife of 43 years, Pat, died of lung cancer.


Robert Winn, MD

Robert Winn, MD

Member

As director of Virginia Commonwealth University VCU Massey Comprehensive Cancer Center, Robert A. Winn, M.D., is leading the nation in establishing a 21st-century model for promoting diversity, equity, and inclusion in the oncology workforce, optimizing cancer health care outcomes for all, and spearheading interdisciplinary approaches to cancer disparities research.